Featured Research

from universities, journals, and other organizations

Costly blood clots more common than expected among cancer patients

Date:
September 20, 2011
Source:
Duke University Medical Center
Summary:
An analysis of more than 30,000 cancer patients has shown that blood clots are a more common complication than doctors may realize, causing additional hospitalizations and driving up the cost of care, according to a new study.

An analysis of more than 30,000 cancer patients has shown that blood clots are a more common complication than doctors may realize, causing additional hospitalizations and driving up the cost of care, according to a study led by a Duke Cancer Institute researcher.

Related Articles


The study, which will be reported Sept. 26 at the 2011 European Multidisciplinary Cancer Congress in Stockholm, found that as many as one in five patients risk developing a blood clot called venous thromboembolism, or VTE, within a year of getting treatment for some types of cancers.

In up to 2 percent of cases the complication is deadly. Clots that form in veins deep in the legs or pelvis can travel to the arteries of the lungs and block blood flow. VTEs are also costly. Cancer patients who develop the clots require medication and hospitalizations that contribute to an average care bill of $110,362, compared to $77,984 for those who do not have VTEs, the study authors reported.

"Direct medical costs of healthcare are significantly greater among cancer patients experiencing a VTE and still do not include caregiver expenses, out of pocket costs and the intangible costs of pain and suffering," said lead author Gary H. Lyman, M.D., M.P.H., a professor of medicine and director of the Comparative Effectiveness and Outcomes Research Program at Duke.

In conducting the study, Lyman and colleagues analyzed 30,552 cancer cases from the InVision™ Data Mart Multiplan/ Integrated Health Care Information Solutions, a large cache of data on more than 17 million U.S. medical patients. The records were of ordinary cancer patients, not participants in clinical trials who tend to be enrolled because they have fewer health issues and therefore develop fewer complications.

The researchers focused on diagnoses of lung, pancreatic, stomach, colon/rectum, bladder and ovarian cancers among patients who began chemotherapy during a four-year period ending in 2008.

Among those in the study group, the risk of developing a VTE within 3.5 months of starting treatment varied widely depending on the type of cancer diagnosed. Bladder cancer carried the lowest risk, at 4.8 percent, and pancreatic cancer had the highest risk, at 11.9 percent. (Colon/rectum 6.1 percent; ovary 6.2 percent; lung 8.5 percent; stomach 8.5 percent)

After a year of treatment, risks nearly doubled across many of the six cancer types, with 9.9 percent of bladder cancer patients and 21.5 percent of pancreatic cancer patients developing clots. (Colon/rectum 11.9 percent; ovary 11.4 percent; lung 14.8 percent; stomach 16.7 percent)

Lyman said scientist don't fully understand why VTEs form during cancer treatment, but have identified certain contributing factors, including blood clotting agents released by tumors, side effects of chemotherapy, and pre-existing health conditions such as obesity and anemia.

He said knowing which patients are at highest risk of developing blood clots could lead to better preventive use of blood thinners. But the preventive use of blood thinners comes with its own risk of potentially dangerous bleeding. A risk score for identifying high risk patients for VTE is based on the type of cancer they have and the other known contributing factors.

"We need more data from randomized control trials in the higher risk populations that would demonstrate a favorable benefit-to-harm ratio from such preventive measures," Lyman said. "Further studies are also needed on the complications of cancer treatment and the associated costs in real-life cancer patients to guide future clinical decisions and more personalized supportive care in patients starting cancer chemotherapy."

In addition to Lyman, study authors included Yanxin Wang; Hongwei Wang; and Alexander T. Cohen.

The study was supported by the pharmaceutical company Sanofi. Lyman received no compensation from Sanofi for his participation.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Costly blood clots more common than expected among cancer patients." ScienceDaily. ScienceDaily, 20 September 2011. <www.sciencedaily.com/releases/2011/09/110920111810.htm>.
Duke University Medical Center. (2011, September 20). Costly blood clots more common than expected among cancer patients. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2011/09/110920111810.htm
Duke University Medical Center. "Costly blood clots more common than expected among cancer patients." ScienceDaily. www.sciencedaily.com/releases/2011/09/110920111810.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins